Sell v. United States

Although 28 U.S.C. § 1291 ordinarily permits appeals only from final criminal judgments, the collateral-order doctrine permits immediate review of a small class of orders that conclusively resolve an important issue separate from the merits and would be effectively unreviewable after final judgment.

The medication order conclusively decided whether Sell had a legal right to refuse the proposed treatment. That question is separate from whether he committed the charged crimes, and it implicates a constitutionally significant interest in bodily integrity and avoiding unwanted medical treatment.

Post-conviction review would come too late to protect the particular right Sell asserted. By the time of trial or appeal, he would already have been forcibly medicated, an intrusion that neither an acquittal nor reversal could undo. A later appeal could address whether medication actually made a trial unfair, but it could not vindicate his right to avoid the medication itself.

The Court began with Washington v. Harper and Riggins v. Nevada, which recognize a significant liberty interest in avoiding unwanted antipsychotic drugs. That interest may be overridden, but only when the Government's justification is sufficiently strong and the proposed treatment is appropriately tailored.

First, a court must find that important governmental interests are at stake. The Government ordinarily has an important interest in prosecuting a defendant accused of a serious crime, including serious property offenses as well as violent offenses. But courts must assess the facts of the particular case because lengthy pretrial confinement, likely future civil commitment, or credit for time served can diminish—though not necessarily eliminate—the practical importance of prosecution.

Second, the court must find that medication will significantly further those governmental interests. The drugs must be substantially likely to restore the defendant's competence, and substantially unlikely to cause side effects that would significantly interfere with the defendant's ability to consult with counsel, react during trial, or otherwise receive a fair trial.

Third, the court must find that involuntary medication is necessary. Less intrusive alternatives, including nondrug treatment or less coercive means of securing medication, must be unlikely to achieve substantially the same result.

Fourth, the court must find that the treatment is medically appropriate—that it is in the patient's best medical interest in light of his particular medical condition. The specific drug regimen matters because different drugs have different efficacy rates and side effects.

Medication to address dangerousness or grave medical risk often presents a more objective and manageable inquiry than medication aimed solely at trial competence. Medical experts may be better able to assess whether particular medication is necessary and appropriate to control dangerous behavior than to evaluate the legal consequences of side effects for competence and trial fairness.

If medication is properly authorized on an alternative ground, the need to decide whether trial competence alone justifies it will ordinarily disappear. And if alternative grounds do not justify medication, the findings from that inquiry can still help courts and experts evaluate the more difficult competence-restoration question.

The Supreme Court assumed, because the Government did not contest the point, that Sell was not dangerous in his institutional setting. On that assumption, the Magistrate's order could not support medication solely for competence because the Magistrate had relied substantially on Sell's supposed dangerousness rather than independently applying a competence-restoration analysis.

The record was developed mainly around dangerousness, not around the trial-specific effects of the proposed drugs. The experts acknowledged significant side effects, but the lower courts had not adequately determined whether those effects could sedate Sell, impair his communication with counsel, limit his ability to respond to trial developments, or otherwise undermine trial fairness.

The lower courts also failed to account for circumstances that could lessen the Government's interest in prosecution, including Sell's already lengthy confinement and the possibility that continued refusal of medication would lead to further institutional confinement. Time already served could reduce any eventual sentence, while future confinement could reduce the risk that Sell would commit additional crimes.

The Government remained free on remand to seek involuntary medication under the standards the Court announced, including on dangerousness grounds. Any renewed request, however, had to rest on current medical and factual circumstances rather than the stale record before the Court.